Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan

Abstract

Background & Objective: Cutaneous Leishmaniasis (CL) is endemic in Baluchistan and treated traditionally with Meglumine antimoniate. Miltefosine appears appealing therapy in cutaneous Leishmaniasis. Our objective was to evaluate safety and efficacy of Miltifossine in treatment of cutaneous Leishmaniasis.
 Methods: This experimental study was conducted from 10 September 2017 to 10 May 2018 at Combined Military Hospital Quetta. Total of 42 patients were recruited by purposive sampling technique. Lesional skin smears were stained with giemsa for Leishmania amastigotes under magnification (100 x).Complete blood count, serum urea, creatinine, bilirubin, aspartate aminotransferases (AST), alanine aminotransferase (ALT) were done at the beginning of treatment and then weekly, thereafter. Cap Miltefosine 50 mg (2.5mg/kg) were given as directly observed therapy .Daily observation during treatment phase was done for clinical side effects of therapy. Clinical response was documented at two weeks then at eight weeks. Photographs were taken before and after the therapy. Data was analyzed by SPSS 16.
 Results: Complete clinical response was observed in 39 (92.9%) patients and partial clinical response in 1(2.4%) patient. Two patients were lost to follow up at eight weeks. No significant derangements in laboratory profile were noted before and after treatment. Mean duration of treatment was 23.47+SD 4.44 days. Sixteen patients (38.1%) took Miltefosine for 28 days, 12 (28.6%) for 21 days and 9 (25%) for 25 days.
 Conclusion: Miltefosine is safe and cost effective treatment for cutaneous Leishmaniasis. It is effective in CL cases not susceptible to antimony compounds.
 How to cite this:Tahir M, Bashir U, Hafeez J, Ghafoor R. Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan. Pak J Med Sci. 2019;35(2):---------. doi: https://doi.org/10.12669/pjms.35.2.54
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Association of systemic inflammation indices with visual field loss progression in patients with primary angle-closure glaucoma: potential biomarkers for 3P medical approaches

“…Venous blood sampling was conducted four times on different days to quantify the number of inflammatory cells in the same participant ( n = 467), revealing that the mean intraindividual CV was below 10% in the complete blood count [ 61 ]. Tahir et al [ 62 ] also reported that no significant difference was noted on different days. The CVs of PLR on different days in the same patient were small, which did not lead to bias in the results.…”

Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review

“…The orally administered drug miltefosine (hexadecylphosphocholine) was first used as an anticancer agent before it was suggested as a treatment for leishmaniasis [ 25 , 50 ]. Studies have proven antileishmanial activities associated with its ability to derange sterol and phospholipid biosynthesis, and cell signal transduction of parasites [ 51 ].…”

“…Studies have proven antileishmanial activities associated with its ability to derange sterol and phospholipid biosynthesis, and cell signal transduction of parasites [ 51 ]. In some instances, where antimony resistance had become a challenge, miltefosine was used as the second-line drug [ 25 ] and was effective on diffused CL producing 80–90% parasitological improvement within 2 months [ 52 ]. Nonetheless, this regime resulted in high probability of relapsing with the development of new infection in the majority of cases [ 52 ].…”

“…To date, a number of antileishmanial treatments have been introduced such as chemotherapy [ 16 ], cryotherapy [ 17 ], thermotherapy [ 18 ] and several less frequently used alternative methods [ 19 ]. Commonly used leishmanicidal drugs include pentavalent antimonials [ 20 – 22 ], amphotericin B [ 23 , 24 ], miltefosine [ 25 , 26 ], paromomycin [ 27 , 28 ] and, topical and systemic azoles [ 29 , 30 ]. These chemotherapeutic agents have immensely helped to reduce CL transmission and alleviate the disease burden over decades.…”

Effectiveness of miltefosine in cutaneous leishmaniasis caused by Leishmania tropica in Pakistan after antimonial treatment failure or contraindications to first line therapy—A retrospective analysis

“…Miltefosine is registered in Pakistan for use in leishmaniasis (produced and sold under the name Fosine). However, until now, only limited case studies have been conducted to evaluate the efficacy of miltefosine in CL caused by L. tropica which is generally considered to be less drug sensitive [24][25][26]. It is not (yet) included in the Pakistan national guidelines, although it is recommended by the WHO in the manual for case management of CL in the EMRO region (2014) as a second line treatment [27,28].…”